42041-51-0

Basic information

• Product Name: 2-Propenoic acid, 3-(4-hydroxy-3,5-dimethoxyphenyl)-, methyl ester, (E)-
• CAS NO: 42041-51-0
• Molecular Formula: C12H14O5
• Molecular Weight: 238.24
• Mol File: 42041-51-0.mol
• Article Data: 36

Chemical Properties

• CAS DataBase Reference: 2-Propenoic acid, 3-(4-hydroxy-3,5-dimethoxyphenyl)-, methyl ester, (E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propenoic acid, 3-(4-hydroxy-3,5-dimethoxyphenyl)-, methyl ester, (E)-(42041-51-0)
• EPA Substance Registry System: 2-Propenoic acid, 3-(4-hydroxy-3,5-dimethoxyphenyl)-, methyl ester, (E)-(42041-51-0)

Safety Data

• Hazardous Substances Data: 42041-51-0(Hazardous Substances Data)

Upstream product

• 186581-53-3 diazomethane 
• 530-59-6 trans-3,5-dimethoxy-4-hydroxycinnamic acid 
• 439944-29-3 (E)-3-(4-Benzyloxy-3,5-dimethoxy-phenyl)-acrylic acid methyl ester 
• 67-56-1 methanol 
• 530-59-6 sinapinic acid 
• 124-41-4 sodium methylate 
• 134-96-3 syringic aldehyde 
• 75-36-5 acetyl chloride 
• 151539-25-2 (E)-3-(4-benzyloxy-3,5-dimethoxy-phenyl)prop-2-enoic acid 
• 6527-32-8 4-(benzyloxy)-3,5-dimethoxybenzaldehyde 
• 21204-67-1 methyl (triphenylphosphoranylidene)acetate 
• 83404-73-3 6'-trans sinapoyl lyaloside 
• 139726-36-6 Tenuifoliside B 

Downstream Products

• 88865-60-5 3-(3,5-dimethoxy-4-hydroxyphenyl)propionic acid methyl ester 
• 20675-96-1 trans-sinapyl alcohol 
• 439944-29-3 (E)-3-(4-Benzyloxy-3,5-dimethoxy-phenyl)-acrylic acid methyl ester 
• 1240483-58-2 8-(4-hydroxy-3,5-dimethoxyphenyl)-7,8-dihydro-6H-[1,3]dioxolo[4,5-g]chromen-6-one 
• 530-59-6 sinapinic acid 
• 1316855-24-9 methyl (E)-3-[2-(4-hydroxy-3,5-dimethoxyphenyl)-7-hydroxy-3-methoxycarbonyl-2,3-dihydro-1-benzofuran-5-yl]propen-2-enoate 
• 1316855-25-0 C₂₄H₂₈O₁₀ 
• 1316855-26-1 methyl (E)-3-[2-(4-hydroxy-3,5-dimethoxyphenyl)-3-methoxycarbonyl-2,3-dihydro-1-4-benzodioxan-7-yl]propen-2-enoate 
• 1316855-23-8 methyl (E)-3-[2-(4-hydroxy-3,5-dimethoxyphenyl)-7-methoxy-3-methoxycarbonyl-2,3-dihydro-1-benzofuran-5-yl]propen-2-enoate 

Relevant articles and documents

One, Two, Three: A Bioorthogonal Triple Labelling Strategy for Studying the Dynamics of Plant Cell Wall Formation In Vivo

Reported herein is an in vivo triple labelling strategy to monitor the formation of plant cell walls. Based on a combination of copper-catalysed alkyne–azide cycloaddition (CuAAC), strain-promoted azide–alkyne cycloaddition (SPAAC), and Diels–Alder reacti

Structure–Activity Relationship Studies of New Sinapic Acid Phenethyl Ester Analogues Targeting the Biosynthesis of 5-Lipoxygenase Products: The Role of Phenolic Moiety, Ester Function, and Bioisosterism

Sinapic acid is found in many edible plants and fruits, such as rapeseed, where it is the predominant phenolic compound. New sinapic acid phenethyl ester (SAPE) analogues were synthesized and screened as inhibitors of the biosynthesis of 5-lipoxygenase (5-LO) in stimulated HEK293 cells and polymorphonuclear leukocytes (PMNL). Inhibition of leukotriene biosynthesis catalyzed by 5-LO is a validated therapeutic strategy against certain inflammatory diseases and allergies. Unfortunately, the only inhibitor approved to date has limited clinical use because of its poor pharmacokinetic profile and liver toxicity. With the new analogues synthesized in this study, the role of the phenolic moiety, ester function, and bioisosterism was investigated. Several of the 34 compounds inhibited the biosynthesis of 5-LO products, and 20 compounds were 2–11 times more potent than zileuton in PMNL, which are important producers of 5-LO products. Compounds 5i (IC50: 0.20 μM), 5l (IC50: 0.20 μM), and 5o (IC50: 0.21 μM) bearing 4-trifluoromethyl, methyl, or methoxy substituent at meta-position of the phenethyl moiety were 1.5 and 11.5 times more potent than SAPE (IC50: 0.30 μM) and zileuton (IC50: 2.31 μM), respectively. Additionally, compound 9 (IC50: 0.27 μM), which was obtained after acetylation of the 4-hydroxyl of SAPE, was equivalent to SAPE and 8 times more active than zileuton. Furthermore, compound 20b (IC50: 0.27 μM) obtained after the bioisosteric replacement of the ester function of SAPE by the 1,2,4-oxadiazole heterocycle was equivalent to SAPE and 8 times more active than zileuton. Thus, this study provides a basis for the rational design of new molecules that could be developed further as anti 5-LO therapeutics.

Synthetic Guaiacol Derivatives as Promising Myeloperoxidase Inhibitors Targeting Atherosclerotic Cardiovascular Disease

Myeloperoxidase (MPO) is known to cause oxidative stress and inflammation leading to cardiovascular disease (CVD) complications. MPO-mediated oxidation of lipoproteins leads to dysfunctional entities altering the landscape of lipoprotein functionality. The specificity of guaiacol derivatives toward preventing MPO-mediated oxidation to limit MPO's harmful effects is unknown. Diligent in silico studies were accomplished for a portfolio of compounds with guaiacol as a building block. The compounds’ activity toward MPO inhibition was also validated. The role of these chemical entities in controlling MPO-mediated oxidation of lipoproteins (LDL and HDL) was shown to agree with our approach of developing powerful MPO inhibitors. The mechanism of MPO inhibition was demonstrated to be reversible in nature. This study reveals that there is great potential for guaiacol derivatives as therapeutics for CVD by modulating lipid profiles, reducing atherosclerotic plaque burden, and subsequently optimizing cardiovascular functions.

Methyl cinnamate type sunscreen molecule, application thereof and sunscreen cream

The invention relates to a compound molecule obtained by introducing different substituents into a benzene ring of methyl cinnamate, and the molecule can be used in the field of sunscreen cream and can be used as a sunscreen molecule. The structure of the